Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000509743> ?p ?o ?g. }
- W2000509743 endingPage "184" @default.
- W2000509743 startingPage "176" @default.
- W2000509743 abstract "Non-systemic vasculitic neuropathy (NSVN) is routinely considered in the differential diagnosis of progressive axonal neuropathies, especially those with asymmetric or multifocal features. Diagnostic criteria for vasculitic neuropathy, classification criteria for NSVN, and therapeutic approaches to NSVN are not standardized. The aim of this guideline was to derive recommendations on the classification, diagnosis, investigation, and treatment of NSVN based on the available evidence and, where evidence was not available, expert consensus. Experts on vasculitis, vasculitic neuropathy, and methodology systematically reviewed the literature for articles addressing diagnostic issues concerning vasculitic neuropathy and NSVN as well as treatment of NSVN and the small-to-medium vessel primary systemic vasculitides using MEDLINE, EMBASE, and the Cochrane Library. The selected articles were analyzed and classified. The group initially reached consensus on a classification of vasculitides associated with neuropathy. Non-diabetic radiculoplexus neuropathy was incorporated within NSVN. The consensus definition of pathologically definite vasculitic neuropathy required that vessel wall inflammation be accompanied by vascular damage. Diagnostic criteria for pathologically probable vasculitic neuropathy included five predictors of definite vasculitic neuropathy: vascular deposits of IgM, C3, or fibrinogen by direct immunofluorescence; hemosiderin deposits; asymmetric nerve fiber loss; prominent active axonal degeneration; and myofiber necrosis, regeneration, or infarcts in peroneus brevis muscle biopsy (Good Practice Points from class II/III evidence). A case definition of clinically probable vasculitic neuropathy in patients lacking biopsy proof incorporated clinical features typical of vasculitic neuropathy: sensory or sensory-motor involvement, asymmetric/multifocal pattern, lower-limb predominance, distal-predominance, pain, acute relapsing course, and non-demyelinating electrodiagnostic features (Good Practice Points from class II/III evidence). Proposed exclusionary criteria for NSVN – favoring the alternate diagnosis of systemic vasculitic neuropathy – were clinicopathologic evidence of other-organ involvement; anti-neutrophil cytoplasmic antibody (ANCAs); cryoglobulins; sedimentation rate ≥100 mm/h; and medical condition/drug predisposing to systemic vasculitis (Good Practice Points supported by class III evidence). Three class III studies on treatment of NSVN were identified, which were insufficient to permit a level C recommendation. Therefore, the group reviewed the literature on treatment of primary small-to-medium vessel systemic vasculitides prior to deriving Good Practice Points on treatment of NSVN. Principal treatment recommendations were: (1) corticosteroid (CS) monotherapy for at least 6 months is considered first-line; (2) combination therapy should be used for rapidly progressive NSVN and patients who progress on CS monotherapy; (3) immunosuppressive options include cyclophosphamide, azathioprine, and methotrexate; (4) cyclophosphamide is indicated for severe neuropathies, generally administered in IV pulses to reduce cumulative dose and side effects; (5) in patients achieving clinical remission with combination therapy, maintenance therapy should be continued for 18–24 months with azathioprine or methotrexate; and (6) clinical trials to address all aspects of treatment are needed." @default.
- W2000509743 created "2016-06-24" @default.
- W2000509743 creator A5007295065 @default.
- W2000509743 creator A5011018483 @default.
- W2000509743 creator A5016933399 @default.
- W2000509743 creator A5030559590 @default.
- W2000509743 creator A5045535997 @default.
- W2000509743 creator A5060657733 @default.
- W2000509743 creator A5061632202 @default.
- W2000509743 creator A5061740194 @default.
- W2000509743 creator A5080861132 @default.
- W2000509743 creator A5082190748 @default.
- W2000509743 creator A5082616069 @default.
- W2000509743 creator A5083732820 @default.
- W2000509743 creator A5088547182 @default.
- W2000509743 date "2010-09-01" @default.
- W2000509743 modified "2023-10-16" @default.
- W2000509743 title "Peripheral Nerve Society Guideline* on the classification, diagnosis, investigation, and immunosuppressive therapy of non-systemic vasculitic neuropathy: executive summary" @default.
- W2000509743 cites W1967804626 @default.
- W2000509743 cites W1972260450 @default.
- W2000509743 cites W1996850533 @default.
- W2000509743 cites W2000664617 @default.
- W2000509743 cites W2033027367 @default.
- W2000509743 cites W2045102209 @default.
- W2000509743 cites W2060038709 @default.
- W2000509743 cites W2091849245 @default.
- W2000509743 cites W2097339734 @default.
- W2000509743 cites W2110884069 @default.
- W2000509743 cites W2121091242 @default.
- W2000509743 cites W2126244459 @default.
- W2000509743 cites W2131217342 @default.
- W2000509743 cites W2132657197 @default.
- W2000509743 cites W2132795660 @default.
- W2000509743 cites W2144944541 @default.
- W2000509743 cites W2150614660 @default.
- W2000509743 cites W2787726068 @default.
- W2000509743 doi "https://doi.org/10.1111/j.1529-8027.2010.00281.x" @default.
- W2000509743 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21040139" @default.
- W2000509743 hasPublicationYear "2010" @default.
- W2000509743 type Work @default.
- W2000509743 sameAs 2000509743 @default.
- W2000509743 citedByCount "206" @default.
- W2000509743 countsByYear W20005097432012 @default.
- W2000509743 countsByYear W20005097432013 @default.
- W2000509743 countsByYear W20005097432014 @default.
- W2000509743 countsByYear W20005097432015 @default.
- W2000509743 countsByYear W20005097432016 @default.
- W2000509743 countsByYear W20005097432017 @default.
- W2000509743 countsByYear W20005097432018 @default.
- W2000509743 countsByYear W20005097432019 @default.
- W2000509743 countsByYear W20005097432020 @default.
- W2000509743 countsByYear W20005097432021 @default.
- W2000509743 countsByYear W20005097432022 @default.
- W2000509743 countsByYear W20005097432023 @default.
- W2000509743 crossrefType "journal-article" @default.
- W2000509743 hasAuthorship W2000509743A5007295065 @default.
- W2000509743 hasAuthorship W2000509743A5011018483 @default.
- W2000509743 hasAuthorship W2000509743A5016933399 @default.
- W2000509743 hasAuthorship W2000509743A5030559590 @default.
- W2000509743 hasAuthorship W2000509743A5045535997 @default.
- W2000509743 hasAuthorship W2000509743A5060657733 @default.
- W2000509743 hasAuthorship W2000509743A5061632202 @default.
- W2000509743 hasAuthorship W2000509743A5061740194 @default.
- W2000509743 hasAuthorship W2000509743A5080861132 @default.
- W2000509743 hasAuthorship W2000509743A5082190748 @default.
- W2000509743 hasAuthorship W2000509743A5082616069 @default.
- W2000509743 hasAuthorship W2000509743A5083732820 @default.
- W2000509743 hasAuthorship W2000509743A5088547182 @default.
- W2000509743 hasConcept C118552586 @default.
- W2000509743 hasConcept C134018914 @default.
- W2000509743 hasConcept C141071460 @default.
- W2000509743 hasConcept C142724271 @default.
- W2000509743 hasConcept C16005928 @default.
- W2000509743 hasConcept C21715850 @default.
- W2000509743 hasConcept C2776015282 @default.
- W2000509743 hasConcept C2777374719 @default.
- W2000509743 hasConcept C2778981458 @default.
- W2000509743 hasConcept C2779134260 @default.
- W2000509743 hasConcept C2779178840 @default.
- W2000509743 hasConcept C2779901536 @default.
- W2000509743 hasConcept C2780052305 @default.
- W2000509743 hasConcept C2780182762 @default.
- W2000509743 hasConcept C2780801072 @default.
- W2000509743 hasConcept C522805319 @default.
- W2000509743 hasConcept C555293320 @default.
- W2000509743 hasConcept C71924100 @default.
- W2000509743 hasConceptScore W2000509743C118552586 @default.
- W2000509743 hasConceptScore W2000509743C134018914 @default.
- W2000509743 hasConceptScore W2000509743C141071460 @default.
- W2000509743 hasConceptScore W2000509743C142724271 @default.
- W2000509743 hasConceptScore W2000509743C16005928 @default.
- W2000509743 hasConceptScore W2000509743C21715850 @default.
- W2000509743 hasConceptScore W2000509743C2776015282 @default.
- W2000509743 hasConceptScore W2000509743C2777374719 @default.
- W2000509743 hasConceptScore W2000509743C2778981458 @default.
- W2000509743 hasConceptScore W2000509743C2779134260 @default.
- W2000509743 hasConceptScore W2000509743C2779178840 @default.
- W2000509743 hasConceptScore W2000509743C2779901536 @default.